January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” Baricitinib is effective and safe for treating severe alopecia areata.
September 2024 in “Skin Appendage Disorders” Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.
September 2025 in “Journal of the American Academy of Dermatology” Some JAK inhibitors are effective for significant hair regrowth in alopecia areata.
December 2017 in “Actas dermo-sifiliográficas/Actas dermo-sifiliográficas” JAK inhibitors show promise for treating Alopecia Areata, while statins are not recommended.
19 citations
,
August 2019 in “Dermatologic therapy” Janus kinase inhibitors show promise for treating alopecia areata but need more research for confirmation.
25 citations
,
March 2021 in “Australasian Journal of Dermatology” Ustekinumab successfully treated a man's resistant skin condition when other treatments failed.
October 2022 in “Journal of Armed Forces Medical College, Bangladesh” Tofacitinib is effective and safe for treating alopecia areata.
70 citations
,
September 2017 in “Expert opinion on therapeutic patents” The review suggests that while many AKR1C3 inhibitors show promise for treating certain cancers, more research is needed to confirm their effectiveness in humans.
Deuruxolitinib is approved to treat severe alopecia areata in adults.
2 citations
,
March 2022 in “Modern Rheumatology Case Reports” A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.
Modern skin cancer treatments can cause skin side effects and hair loss, affecting patients' quality of life.
12 citations
,
December 2022 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.
April 2025 in “Anais Brasileiros de Dermatologia” Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.
44 citations
,
May 2023 in “MedComm” PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” Machine learning can predict how well patients with alopecia areata will respond to certain treatments.
August 2025 in “Acta Dermato Venereologica”
1 citations
,
April 2016 in “Journal of The American Academy of Dermatology” Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.
1 citations
,
July 2024 in “Journal of Investigative Dermatology” TAK-279 effectively reduces psoriasis symptoms and is safe.
66 citations
,
June 2021 in “Journal of The American Academy of Dermatology” Baricitinib is effective and safe for treating severe alopecia areata.
November 2025 in “Mendeley Data” Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.
December 2023 in “Journal of Cosmetic Dermatology” Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.
August 2018 in “Journal of the American Academy of Dermatology” Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.
June 2025 in “BMJ Case Reports” Axitinib treatment turned a man's grey hair back to black.
Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.
1 citations
,
January 2020 in “Surgical & Cosmetic Dermatology” Combining oral minoxidil with JAK inhibitors helps regrow hair in severe alopecia areata cases.
2 citations
,
February 2014 in “Journal of Crohn's and colitis” Some IBD patients on anti-TNFs developed severe skin issues, but ustekinumab helped.
July 2024 in “Journal of Investigative Dermatology” Baicalin may help treat severe drug-induced skin reactions.
4 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
May 2019 in “Journal of clinical oncology” Topical calcitriol was safe and well-tolerated for potential hair loss prevention in chemotherapy patients.
November 2024 in “Journal of Cosmetic Dermatology” Baricitinib is effective for severe alopecia areata but has some side effects.